exenatide and Granuloma

exenatide has been researched along with Granuloma* in 2 studies

Other Studies

2 other study(ies) available for exenatide and Granuloma

ArticleYear
Carbol fuchsin stain enhances detection of poly-(d, l-lactide-co-glycolide) microspheres in exenatide extended-release cutaneous injection-site foreign body reaction.
    Journal of cutaneous pathology, 2021, Volume: 48, Issue:12

    Injection of high-viscosity fluids into subcutaneous tissues may lead to a granulomatous reaction called sclerosing lipogranuloma (SL). Poly-(d,l-lactide-co-glycolide) (PLG or PLGA) microspheres are used as vehicles for extended-release drugs. Here we describe the histopathologic features of a case of SL induced by exenatide extended-release injections, and the staining pattern of PLG microspheres and microsphere remnants with carbol fuchsin.

    Topics: Coloring Agents; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Carriers; Exenatide; Female; Foreign-Body Reaction; Granuloma; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Microspheres; Middle Aged; Polylactic Acid-Polyglycolic Acid Copolymer; Rosaniline Dyes

2021
Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection site.
    The American Journal of dermatopathology, 2014, Volume: 36, Issue:6

    Sclerosing lipogranuloma is a granulomatous reaction to the injection of a high-viscosity fluid in the tissues for the cosmetic purpose of improving body contour; lesions on the extremities and buttocks are commonly the results of injections of therapeutic agents in oily vehicles. Exenatide, once-weekly injection, is a therapeutic method for patients with type 2 diabetes. Here, we describe a case of exenatide once weekly induced eosinophilic sclerosing lipogranuloma at the injection site of a 62-year-old patient. To the best of our knowledge, the histopathologic features of this adverse event have not been reported in the medical literature.

    Topics: Diabetes Mellitus, Type 2; Eosinophilia; Exenatide; Granuloma; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Male; Middle Aged; Panniculitis; Peptides; Skin Diseases; Venoms

2014